- BBG Advanced Therapies and CELLforCURE enhance global CDMO capacity for ATMPs.
- BBGAT offers 9 cGMP cleanrooms and a mobile leukapheresis center.
- CELLforCURE provides 10,000 m² facility with 7 manufacturing lines.
- The partnership supports rapid scaling and multinational trials.
Partnership Overview
BBG Advanced Therapies, a subsidiary of BioBridge Global, and CELLforCURE, part of SEQENS Group, have formed a partnership to enhance the development and production of Advanced Therapy Medicinal Products (ATMPs). This collaboration creates a transatlantic connection, allowing U.S. companies to utilize CELLforCURE’s European manufacturing capabilities, while European companies can access BBG Advanced Therapies’ U.S. facilities.
BBG Advanced Therapies Capabilities
BBG Advanced Therapies integrates cell and tissue expertise with advanced biomanufacturing capabilities, adhering to FDA, EMA, and PMDA regulations. Their services cover leukapheresis, donor management, testing, cryopreservation, biomanufacturing, and assay development, all under a unified Quality Management System. The facility includes 9 cGMP cleanrooms and a mobile leukapheresis center.
CELLforCURE Facilities
CELLforCURE offers a 10,000 m² facility with 3,000 m² of GMP-certified areas across 7 independent manufacturing lines, each with 8 cleanrooms. The company has a strong track record in CAR-T manufacturing and immune cell therapies, ensuring high-quality drug product delivery through in-house Quality Control for 90% of processes.
Impact on ATMP Development
This partnership aims to remove barriers in ATMP manufacturing, creating a scalable, global CDMO network that accelerates the journey from concept to commercialization. By combining expertise and infrastructure, the collaboration supports rapid scaling, multinational trials, and improved patient access to therapies.
